BIOMAT Database Logo BIOMAT Database Logo

[Adherence and toxicity to tyrosine kinase inhibitor therapy in chronic myeloid leukemia]. 2013

V González Rosa, and F Gutiérrez Nicolás, and R Gavira Moreno, and M M Viña Romero, and M T Moreno Carvajal, and R Gázquez Pérez
Hospital General Jerez de la Frontera. Cádiz.

OBJECTIVE To analyze adherence and toxicity of tyrosine kinase inhibitor (TKIs) therapy in patients diagnosed with chronic myeloid leukemia (CML). METHODS A 18-months retrospective observational study (January 2011-June 2012) which included all patients diagnosed with CML in a secondary hospital (550 beds) and were treated with imatinib, dasatinib or nilotinib. It was collected the following variables: sex, age at diagnosis, years of treatment and side effects. Adherence was evaluated using SMAQ questionnaire and recording dispensations. RESULTS 25 patients were included and all but two (92.0%) experienced side effects to imatinib,83.3% to dasatinib and 66.7% to nilotinib. The average adherence was 71.3%. There was identified as possible parameters of lack of adherence the female patients (55.6 % vs. 66.7%, p = 0.586), older than 50 (55.6 % vs. 83.3 %, p = 0.125), more than four years of treatment (70.0 % vs. 57.1 %, p = 0.521) and the presence of certain side effects (gastrointestinal disorders and musculoeskeletal pain). CONCLUSIONS Almost one third of patients were considered nonadherent to therapy. Although the sample size did not allow us to establish a statistically significant relation between adherence and the variables analyzed, the clinical relevance of these results show the importance of future studies with larger populations to confirm the trends established in this study.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010349 Patient Compliance Voluntary cooperation of the patient in following a prescribed regimen. Client Adherence,Client Compliance,Non-Adherent Patient,Patient Adherence,Patient Cooperation,Patient Noncompliance,Patient Non-Adherence,Patient Non-Compliance,Patient Nonadherence,Therapeutic Compliance,Treatment Compliance,Adherence, Client,Adherence, Patient,Client Compliances,Compliance, Client,Compliance, Patient,Compliance, Therapeutic,Compliance, Treatment,Cooperation, Patient,Non Adherent Patient,Non-Adherence, Patient,Non-Adherent Patients,Non-Compliance, Patient,Nonadherence, Patient,Noncompliance, Patient,Patient Non Adherence,Patient Non Compliance,Patient, Non-Adherent,Therapeutic Compliances,Treatment Compliances
D010879 Piperazines Compounds that are derived from PIPERAZINE.
D011505 Protein-Tyrosine Kinases Protein kinases that catalyze the PHOSPHORYLATION of TYROSINE residues in proteins with ATP or other nucleotides as phosphate donors. Tyrosine Protein Kinase,Tyrosine-Specific Protein Kinase,Protein-Tyrosine Kinase,Tyrosine Kinase,Tyrosine Protein Kinases,Tyrosine-Specific Protein Kinases,Tyrosylprotein Kinase,Kinase, Protein-Tyrosine,Kinase, Tyrosine,Kinase, Tyrosine Protein,Kinase, Tyrosine-Specific Protein,Kinase, Tyrosylprotein,Kinases, Protein-Tyrosine,Kinases, Tyrosine Protein,Kinases, Tyrosine-Specific Protein,Protein Kinase, Tyrosine-Specific,Protein Kinases, Tyrosine,Protein Kinases, Tyrosine-Specific,Protein Tyrosine Kinase,Protein Tyrosine Kinases,Tyrosine Specific Protein Kinase,Tyrosine Specific Protein Kinases
D011743 Pyrimidines A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
D011795 Surveys and Questionnaires Collections of data obtained from voluntary subjects. The information usually takes the form of answers to questions, or suggestions. Community Survey,Nonrespondent,Questionnaire,Questionnaires,Respondent,Survey,Survey Method,Survey Methods,Surveys,Baseline Survey,Community Surveys,Methodology, Survey,Nonrespondents,Questionnaire Design,Randomized Response Technique,Repeated Rounds of Survey,Respondents,Survey Methodology,Baseline Surveys,Design, Questionnaire,Designs, Questionnaire,Methods, Survey,Questionnaire Designs,Questionnaires and Surveys,Randomized Response Techniques,Response Technique, Randomized,Response Techniques, Randomized,Survey, Baseline,Survey, Community,Surveys, Baseline,Surveys, Community,Techniques, Randomized Response
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000068877 Imatinib Mesylate A tyrosine kinase inhibitor and ANTINEOPLASTIC AGENT that inhibits the BCR-ABL kinase created by chromosome rearrangements in CHRONIC MYELOID LEUKEMIA and ACUTE LYMPHOBLASTIC LEUKEMIA, as well as PDG-derived tyrosine kinases that are overexpressed in gastrointestinal stromal tumors. Alpha-(4-methyl-1-piperazinyl)-3'-((4-(3-pyridyl)-2-pyrimidinyl)amino)-p-tolu-p-toluidide,CGP 57148,CGP-57148,CGP57148B,Gleevec,Glivec,Imatinib,Imatinib Methanesulfonate,ST 1571,ST1571,STI 571,STI-571,STI571,CGP57148,Mesylate, Imatinib,Methanesulfonate, Imatinib

Related Publications

V González Rosa, and F Gutiérrez Nicolás, and R Gavira Moreno, and M M Viña Romero, and M T Moreno Carvajal, and R Gázquez Pérez
Patient adherence to tyrosine kinase inhibitor therapy in chronic myeloid leukemia.
July 2012, American journal of hematology,
V González Rosa, and F Gutiérrez Nicolás, and R Gavira Moreno, and M M Viña Romero, and M T Moreno Carvajal, and R Gázquez Pérez
Adherence to oral tyrosine kinase inhibitor therapies in chronic myeloid leukemia.
July 2012, Leukemia research,
V González Rosa, and F Gutiérrez Nicolás, and R Gavira Moreno, and M M Viña Romero, and M T Moreno Carvajal, and R Gázquez Pérez
Cardiovascular Toxicity Associated With Tyrosine Kinase Inhibitor Therapy In Chronic Myeloid Leukemia.
September 2021, The Gulf journal of oncology,
V González Rosa, and F Gutiérrez Nicolás, and R Gavira Moreno, and M M Viña Romero, and M T Moreno Carvajal, and R Gázquez Pérez
Survival impact of adherence to tyrosine kinase inhibitor in chronic myeloid leukemia.
November 2021, The Korean journal of internal medicine,
V González Rosa, and F Gutiérrez Nicolás, and R Gavira Moreno, and M M Viña Romero, and M T Moreno Carvajal, and R Gázquez Pérez
Tyrosine kinase inhibitor associated vascular toxicity in chronic myeloid leukemia.
December 2015, Cardio-oncology (London, England),
V González Rosa, and F Gutiérrez Nicolás, and R Gavira Moreno, and M M Viña Romero, and M T Moreno Carvajal, and R Gázquez Pérez
Tyrosine Kinase Inhibitor-Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia.
December 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
V González Rosa, and F Gutiérrez Nicolás, and R Gavira Moreno, and M M Viña Romero, and M T Moreno Carvajal, and R Gázquez Pérez
Tailoring tyrosine kinase inhibitor therapy in chronic myeloid leukemia.
April 2009, Cancer control : journal of the Moffitt Cancer Center,
V González Rosa, and F Gutiérrez Nicolás, and R Gavira Moreno, and M M Viña Romero, and M T Moreno Carvajal, and R Gázquez Pérez
Adherence to tyrosine kinase inhibitor therapy for chronic myeloid leukemia: a Brazilian single-center cohort.
January 2013, Acta haematologica,
V González Rosa, and F Gutiérrez Nicolás, and R Gavira Moreno, and M M Viña Romero, and M T Moreno Carvajal, and R Gázquez Pérez
Adherence to tyrosine kinase inhibitor and clinical outcomes in patients with chronic myeloid leukemia.
November 2023, International immunopharmacology,
V González Rosa, and F Gutiérrez Nicolás, and R Gavira Moreno, and M M Viña Romero, and M T Moreno Carvajal, and R Gázquez Pérez
Managing chronic myeloid leukemia patients intolerant to tyrosine kinase inhibitor therapy.
October 2012, Blood cancer journal,
Copied contents to your clipboard!